Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026

Maze Therapeutics, Inc.

2025-Q3 EPS reported -$2.45 vs consensus -$0.72 ▼ miss (-239.0%)

Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.
Cash, equivalents and marketable securities $383.9M as of Sep 30, 2025; runway into 2028 after $150M private placement.
MZE782 Phase 1 positive: well-tolerated, dose-dependent urinary Phe and glutamine increase; eGFR dip observed.
MZE782 Phase 2 trials in PKU and CKD expected to initiate in 2026; MZE829 HORIZON topline data by Q1 2026.
Appointed Hervé Hoppenot as chairman and Misbah Tahir as CFO in Sep/Oct 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.